Ligand Pharmaceuticals Incorporated Cash Flow Conversion Efficiency
Ligand Pharmaceuticals Incorporated cash flow conversion efficiency. Based on the latest financial reports, Ligand Pharmaceuticals Incorporated (LGND) has a cash flow conversion efficiency ratio of 0.025x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($24.02 Million) by net assets ($967.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Ligand Pharmaceuticals Incorporated stock valuation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Ligand Pharmaceuticals Incorporated (1994–2025)
Cash flow conversion efficiency of Ligand Pharmaceuticals Incorporated from 1994 to 2025. This chart illustrates how Ligand Pharmaceuticals Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Ligand Pharmaceuticals Incorporated stock price today for real-time trading data and today's change.
Ligand Pharmaceuticals Incorporated Cash Flow Conversion Ratio Explained
Ligand Pharmaceuticals Incorporated cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ligand Pharmaceuticals Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ligand Pharmaceuticals Incorporated ranked by their cash flow conversion efficiency. Review LGND free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Molybdenum Co. Ltd
F:D7N
|
0.038x |
|
Definity Financial Corp
TO:DFY
|
-0.030x |
|
Turkiye Halk Bankasi
IS:HALKB
|
-0.126x |
|
Shanxi LuAn Environmental Energy Development Co Ltd
SHG:601699
|
0.074x |
|
COVIVIO UNS.ADR/1/4
F:F5D0
|
N/A |
|
Adani Total Gas Limited
NSE:ATGL
|
0.017x |
|
Telekom Austria AG
VI:TKA
|
0.095x |
|
China Natl Chem Engineering Co
SHG:601117
|
0.091x |
Annual Cash Flow Conversion Efficiency for Ligand Pharmaceuticals Incorporated (1994–2025)
The table below shows the annual cash flow conversion efficiency of Ligand Pharmaceuticals Incorporated from 1994 to 2025. Also see Ligand Pharmaceuticals Incorporated total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.02 Billion | $49.36 Million | 0.049x | -58.48% |
| 2024-12-31 | $830.44 Million | $97.05 Million | 0.117x | +65.22% |
| 2023-12-31 | $700.91 Million | $49.58 Million | 0.071x | -69.34% |
| 2022-12-31 | $597.49 Million | $137.85 Million | 0.231x | +140.43% |
| 2021-12-31 | $821.16 Million | $78.80 Million | 0.096x | +24.73% |
| 2020-12-31 | $709.52 Million | $54.59 Million | 0.077x | +301.21% |
| 2019-12-31 | $767.23 Million | $-29.34 Million | -0.038x | -111.05% |
| 2018-12-31 | $560.91 Million | $194.06 Million | 0.346x | +54.80% |
| 2017-12-31 | $418.65 Million | $93.57 Million | 0.224x | +31.56% |
| 2016-12-31 | $370.85 Million | $63.00 Million | 0.170x | +23.93% |
| 2015-12-31 | $304.39 Million | $41.73 Million | 0.137x | -83.73% |
| 2014-12-31 | $24.41 Million | $20.57 Million | 0.843x | +102.05% |
| 2013-12-31 | $49.61 Million | $20.69 Million | 0.417x | +6760.24% |
| 2012-12-31 | $26.48 Million | $161.00K | 0.006x | +104.48% |
| 2011-12-31 | $8.65 Million | $-1.17 Million | -0.136x | -103.50% |
| 2010-12-31 | $-6.99 Million | $-27.07 Million | 3.872x | +142.89% |
| 2009-12-31 | $3.74 Million | $-33.80 Million | -9.028x | -553.70% |
| 2008-12-31 | $-10.37 Million | $-20.62 Million | 1.990x | +159.28% |
| 2007-12-31 | $29.11 Million | $-97.73 Million | -3.357x | +33.72% |
| 2006-12-31 | $27.35 Million | $-138.52 Million | -5.064x | -6585.05% |
| 2005-12-31 | $-110.42 Million | $8.37 Million | -0.076x | +0.84% |
| 2004-12-31 | $-75.32 Million | $5.75 Million | -0.076x | -2072.05% |
| 2003-12-31 | $70.73 Million | $274.00K | 0.004x | +101.14% |
| 2002-12-31 | $74.02 Million | $-25.11 Million | -0.339x | -198.64% |
| 2001-12-31 | $-57.88 Million | $-19.91 Million | 0.344x | -59.96% |
| 2000-12-31 | $-55.12 Million | $-47.35 Million | 0.859x | -63.65% |
| 1999-12-31 | $-25.60 Million | $-60.50 Million | 2.363x | -59.55% |
| 1998-12-31 | $-11.40 Million | $-66.60 Million | 5.842x | +1595.40% |
| 1997-12-31 | $34.30 Million | $-13.40 Million | -0.391x | +59.53% |
| 1996-12-31 | $34.50 Million | $-33.30 Million | -0.965x | +28.44% |
| 1995-12-31 | $28.10 Million | $-37.90 Million | -1.349x | -148.06% |
| 1994-12-31 | $26.30 Million | $-14.30 Million | -0.544x | -- |
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help figh… Read more